US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.
Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.
India’s Delhi High Court has dismissed a petition for an injunction by German pharma company Bayer against an Indian competitor.
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.
US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.
The UK Intellectual Property Office has today, July 5, opened a consultation into supplementary protection certificate law in the event of a ‘no deal’ Brexit.